LYEL vs. ORIC, PHAR, ZYME, SLN, OLMA, GHRS, CVAC, STOK, PAHC, and CALT
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include ORIC Pharmaceuticals (ORIC), Pharming Group (PHAR), Zymeworks (ZYME), Silence Therapeutics (SLN), Olema Pharmaceuticals (OLMA), GH Research (GHRS), CureVac (CVAC), Stoke Therapeutics (STOK), Phibro Animal Health (PAHC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
ORIC Pharmaceuticals has a net margin of 0.00% compared to ORIC Pharmaceuticals' net margin of -335,794.09%. ORIC Pharmaceuticals' return on equity of -33.92% beat Lyell Immunopharma's return on equity.
ORIC Pharmaceuticals received 33 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 65.71% of users gave ORIC Pharmaceuticals an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
ORIC Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500.
ORIC Pharmaceuticals currently has a consensus price target of $20.00, indicating a potential upside of 118.34%. Lyell Immunopharma has a consensus price target of $5.50, indicating a potential upside of 100.73%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Lyell Immunopharma.
ORIC Pharmaceuticals has higher earnings, but lower revenue than Lyell Immunopharma. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, ORIC Pharmaceuticals had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for ORIC Pharmaceuticals and 4 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.08 beat ORIC Pharmaceuticals' score of 0.76 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media.
Summary
ORIC Pharmaceuticals beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
